This page features members of the Global Pharmacovigilance network and their stories about how they came to work or have an interest in Pharmacovigilance.
Ernest Dela Dzidzornu - Ernest works in the Department of Pharmacovigilance and Regulatory Affairs as a QPPV at Salom Pharmacy Limited, Kumasi, Ghana. One of Ernest's many interests is finding ways to boost the spontaneous ADR reporting rates in Ghana.
Frider Chimimba - Pharmacist and lecturer at the Pharmacy Department, College of Medicine, University of Malawi. Recently, Frider has also played an important part in the establishment of the Malawi National Pharmacovigilance Centre.
Max Schurer - Industrial Engineering PhD student, Stellenbosch University, South Africa. Max's research focuses on the interoperability of spontaneous reporting systems (SRSs) in PV, specifically guiding SRSs towards interoperability through the introduction of a capability maturity model.
Biancé Huysamen - Masters student in Industrial Engineering, Stellenbosch University, South Africa. Biancé's research focuses on how niche environmental factors affect drug safety monitoring systems and the development of a conceptual framework for a 'Niche PV System' that will take the unique needs of these factors into account.
Walter-Rodney Nagumo - PhD candidate at the University of Sheffield, in the School of Health and Related Research (ScHARR), Public Health Section. Rodney's research is aimed at understanding pharmacovigilance and ADR reporting practices among healthcare professionals in Ghana.
Cheryl Pace - Pharmacovigilance Pharmacist at the Liverpool School of Tropical Medicine, UK. Cheryl has a background in hospital pharmacy inlcuidng two years spent practicing in Uganda.
Elizabeth Allen - Head of Clinical Research at the Collaborating Centre for Optimising Antimalarial Therapy (CCOAT), University of Cape Town. Liz has a research interest in the assessment of drug safety in clinical trials.
Paul Cross - GCP Quality Assurance Manager at Guy's and St Thomas' NHS Foundation Trust. Paul has a research interest in patient and public involvement and engagement (PPIE) and pharmacovigilance in clinical trials.